Bicara Therapeutics (NASDAQ: BCAX) CEO exercises options, sells 36,766 shares

Rhea-AI Filing Summary

Bicara Therapeutics Inc. Chief Executive Officer Claire Mazumdar exercised options to acquire 36,766 shares of common stock at an exercise price of $3.7898 per share on March 9, 2026. She then sold 36,766 shares of common stock at a weighted average price of $19.1660 per share in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 12, 2025. Following these transactions, she directly holds 339,392 shares of Bicara Therapeutics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazumdar Claire

(Last) (First) (Middle)

BICARA THERAPEUTICS INC.

116 HUNTINGTON AVENUE, SUITE 703

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bicara Therapeutics Inc. [ BCAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		M(1)		36,766	A	$3.7898	376,158	D
Common Stock	03/09/2026		S(1)		36,766	D	$19.166(2)	339,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7898	03/09/2026		M(1)			36,766	(3)	08/08/2033	Common Stock	36,766	$0	191,107	D

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.73 to $19.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.

Remarks:

	/s/ Lara Meisner, Attorney-in-Fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Bicara Therapeutics (BCAX) report for its CEO?

Bicara Therapeutics reported that CEO Claire Mazumdar exercised options for 36,766 shares and sold 36,766 common shares on March 9, 2026. These transactions reflect an option exercise followed by a sale of the acquired shares in the open market.

At what prices did the BCAX CEO exercise and sell shares in this Form 4?

CEO Claire Mazumdar exercised stock options at an exercise price of $3.7898 per share and sold 36,766 common shares at a weighted average price of $19.1660. The sale price reflects multiple trades between $18.73 and $19.64 per share.

How many Bicara Therapeutics (BCAX) shares does the CEO hold after these transactions?

After exercising options and selling shares, CEO Claire Mazumdar directly holds 339,392 shares of Bicara Therapeutics common stock. This figure comes from the post-transaction ownership reported in the Form 4 for the March 9, 2026 transactions.

Were the Bicara Therapeutics (BCAX) CEO share sales under a Rule 10b5-1 plan?

Yes. The Form 4 states the March 9, 2026 share sales were executed under a Rule 10b5-1 trading plan adopted on February 12, 2025. Such plans pre-schedule trades, indicating the timing was set in advance rather than decided opportunistically.

What type of derivative security did the BCAX CEO exercise in this filing?

The CEO exercised a stock option, described as a “Stock Option (Right to Buy)” for 36,766 underlying common shares. The option carries an exercise price of $3.7898 per share and an expiration date of August 8, 2033, with vesting in equal quarterly installments.